Meeting
2023 ASCO Annual Meeting
In silico approaches to patient selection: Credentialing elraglusib as a novel treatment in metastatic melanoma resistant to checkpoint inhibitors.
Authors
Joseph McDermott
Lantern Pharma, Dallas, TX
Joseph McDermott , Taylor Weiskittel , Brittany Borden , Ludimila Cavalcante , Francis J. Giles , Benedito A. Carneiro , Hu Li , Andrew Paul Mazar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Clinical Trial Registration Number
NCT03678883
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3079)
DOI
10.1200/JCO.2023.41.16_suppl.3079
Abstract #
3079
Poster Bd #
277
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Clinical value of noninvasive biomarkers reflecting a collagen-rich stroma in metastatic melanoma patients treated with anti-PD1 therapy.
First Author: Christina Jensen
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Autoimmune toxicities with anti-PD-1 treatment of metastatic melanoma in predominantly older patients: A single institutional experience.
First Author: Harsh V Parmar
Poster
2018 ASCO Annual Meeting
A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13.
First Author: Tara D. Baetz
Poster
2017 ASCO Annual Meeting
Analysis of circulating tumor DNA (ctDNA) in pseudoprogression in anti-PD1 treated metastatic melanoma (MM).
First Author: Jenny HJ Lee